Therapeutic perspectives for type 2 diabetes mellitus: Molecular and clinical insights

Diabetes and Metabolism

Volumn 27, Issue 4 I, 2001, Pages 415-423

  Mauvais Jarvis, F ^a   Andreelli, F ^a   Hanaire Broutin, H ^a   Charbonnel, B ^a   Girard, J ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Glucagon like peptide 1; Insulin resistance; Thiazolidinediones; Treatment; Type 2 diabetes

Indexed keywords

ADENYLATE KINASE; FARGLITAZAR; GLUCAGON LIKE PEPTIDE 1; MEGLITINIDE; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; VANADIUM;

CELL FUNCTION; CELL PROTECTION; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GENE THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; THIAZOLES;

EID: 0034858134     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. The U.K. Prospective Diabetes Study. A review
2. Pharmacologic therapy for type 2 diabetes mellitus
3. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease
4. PPARgamma and the treatment of insulin resistance
5. Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat
6. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
7. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
8. Mechanism of troglitazone action in type 2 diabetes
9. Roziglitazone reduces hepatic fat content
10. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
11. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets
12. Rosiglitazone reduces net loss of pancreatic beta-cell mass in Zucker diabetic fatty rat
13. Metabolic and vascular effects of the thiazolidinedione troglitazone
14. Nonhypoglycemic effects of thiazolidinediones
15. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
16. PPARgamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
17. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAl pathway
18. Unraveling the mechanism of action of thiazolidinediones
19. Proinsulin/insulin ratio reduced and beta-cell function improved in type 2 diabetes with roziglitazone
20. Improved insulin sensitivity and beta-cell responsivity suggested by HOMA analysis of pioglitazone therapy
21. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review
22. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
23. Rosiglitazone
24. Pioglitazone
25. Pioglitazone
26. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
27. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
28. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
29. Thiazolidinediones: An update
30. Potential new treatments for type 2 diabetes
31. Monotherapy with GI262570, a non-thiazolidinedione PPAR gamma agonist, improves glycemic control in type 2 diabetes mellitus patients
32. BM 17.0744: A structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity
33. In vivo effects of a dual activator of peroxisome proliferator-activated receptor(PPAR) alpha and gamma: LR 90
34. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus
35. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes
36. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate
37. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus
38. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
39. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies
40. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C
41. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
42. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice
43. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B
44. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
45. PTPIB inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes
46. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle
47. Exercise, glucose transport, and insulin sensitivity
48. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport
49. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle
50. AICAR treatment improves glucose homeostasis in ob/ob mice
51. Increased whole body glucose tolerance and muscle glycogen and GLUT-4 content in Zucker obese rats after five days treatment with AICAR
52. AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) ameliorates hyperglycemia and hyperinsulinemia in type 2 diabetic mice
53. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
54. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators
55. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin
56. Nateglinide
57. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
58. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
59. Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal excursions with less total insulin exposure
60. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide
61. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
62. Glucagon-like peptides
63. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
64. Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function
65. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
66. The GLP-1 analogue LY307161, potently lowers postprandial blood glucose in subjects with type 2 diabetes
67. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations
68. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
69. Subcutaneous exendin-4 improves 24 hour glucose exposure in type 2 diabetes
70. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
71. Prodrugs of PP-IV-inhibitors strongly improve incretin-mediated glucose tolerance
72. Single dose treatment of type 2 diabetics by the DP-IV-inhibitor P32/98
73. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients
74. Recent developments and emerging therapies for type 2 diabetes mellitus
75. Present and potential future use of gene therapy for the treatment of non-insulin dependent diabetes mellitus
76. Glucose-dependent insulin release from genetically engineered K cells
77. Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus
78. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus
79. Human gene therapy
80. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum
81. Improvement of insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle
82. Enhanced insulin action due to targeted GLUT4 overexpression exclusively in muscle
83. Correction of diabetic alterations by glucokinase
84. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression